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Abstract 
Review on t(4;9)(q21.22;p24)  SEC31A/JAK2, with 
data on clinics, and the genes involved. 
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Clinics and pathology 
Disease 
Hodgkin Lymphoma 
Phenotype/cell stem origin 
Hodgkin and Reed-Sternberg cells, which derive 
from pre-apoptotic crippled germinal center (GC) B-
cells, are positive for CD30, CD15, CD40 and 
IRF4/MUM1 
Epidemiology 
Hodgkin lymphoma itself is common, but this 
particular translocation may be rare within the 
disorder.  However, it is not often assayed for; found 
in 2/131 cHL cases examined: a M/31 with nodular 
sclerosis cHL, alive 60 mths after diagnosis; and a 
M/83 with lymphocyte-depleted cHL who died at 
day 14 (Van Roosbroeck et al, 2011). 
Treatment 
SEC31A/JAK2 acts as a constitutively activated 
tyrosine kinase and is sensitive to JAK2 inhibition 
Prognosis 
Yet unknown. 
Cytogenetics 
Cytogenetics morphological 
JAK2 breakapart (commonly available). 
Genes involved and 
proteins 
SEC31A (SEC31 homolog A, COPII 
coat complex component) 
Location 
4q21.22 
DNA/RNA 
gene is 72,606 bp with 25 exons; transcribed from 
the - strand; coding region is 62,863 bp with 24 
exons 
Protein 
1166 amnio acids. Protein transport protein SEC31A 
is ubiquitously expressed and forms part of the coat 
protein complex II (COPII) which is comprised of at 
least four other proteins in addition to SEC31A this 
complex is involved in formation of transport 
vesicles from the ER to Golgi.  Protein localized to 
the cytoplasmic side of the cell membrane and is 
GTP-dependent. 
JAK2 (janus kinase 2) 
Location 
9p24.1 
DNA/RNA 
t0409q21p24ID1682  
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143,098 bp with 24 exons; transcribed from the + 
strand; coding region is 104,804 bp with 23 exons. 
 
Protein 
Protein is 1132 amino acids with multiple functional 
domains; regulated by auto-phosphorylation. Non-
receptor protein tyrosine kinase, ubiquitously 
expressed. 
Germinal mutations 
Germline mutations associated with autosomal 
dominant Familial Thrombocythemia 
Somatic mutations 
'Gain of Function' V617F mutation and mutations in 
exon 12 of the gene common in patients with 
Polycythemia Vera, Myelofibrosis with Myeloid 
Metaplasia or idiopathic erythrocytosis. 
Result of the chromosomal 
anomaly 
Hybrid gene 
Note 
Fusion results in 5' SEC31A fused to 3' partner gene 
JAK2 
Description 
Exon 22 SEC31A is fused with exon 17 of JAK2 in 
the two reported cases (Van Roosbroeck et al, 2011) 
Detection 
 
FISH using JAK2 and SEC31A breakapart probes, 
rtPCR or RNAseq. 
Fusion protein 
Oncogenesis 
The fusion protein is a constitutively activated 
tyrosine kinase: JAK2 activation is mediated by a 
domain region of SEC31A that lies between the WD-
40-like and proline-rich domains of the protein (Van 
Roosbroeck et al, 2011). 
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